Retatrutide + Tirzepatide (Blend)

Overview

This research preparation combines Retatrutide (LY3437943, a triple GLP-1/GIP/glucagon receptor agonist) and Tirzepatide (LY3298176, a dual GIP/GLP-1 receptor agonist) in a single vial at a fixed 20 mg + 40 mg ratio. Both are incretin-mimetic peptides with independent Phase 3 clinical data for their individual effects; the fixed combination itself has not been evaluated in a dedicated clinical trial and is supplied for research use only. Vialdyne co-formulates Retatrutide + Tirzepatide (Blend) to the stated ratio and releases it with a batch-specific Certificate of Analysis reporting per-component identity, RP-HPLC purity, and fill accuracy. The component breakdown is documented on the lot COA.

Applications & buyer fit

Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

(blend — Retatrutide 2381089-83-2 + Tirzepatide 2023788-19-2)

Appearance

White lyophilized powder

Purity (HPLC)

See per-component COA

Strength

60 mg

Packaging

10 vials/box · base pack (multiples of 10)

MOQ

On request

Lead time

10–18 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Frequently asked questions